Telomere Binding Protein Antagonists for Stem Cell Therapy Public Deposited

http://ir.library.oregonstate.edu/concern/undergraduate_thesis_or_projects/tx31qk55v

June 2011

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Abstract Understanding the mechanisms through which stem cells self-renew is important for the development of new therapies to repair and restore damaged tissue. This research explores possible mechanisms of telomere mimic action and seeks to validate a new assay for evaluating telomere binding antagonists and studying the effects of telomere binding antagonists on stem cells. This project is important for screening potential drug properties for use in bone marrow therapy and identifying new reagents to modulate stem cell growth and differentiation. This study is designed to test the hypothesis that our labeled telomere ‘mimics’ will interact with telomere binding proteins to modify the binding profile within the nucleus. Modulation of telomere binding proteins at the telomere could potentially explain the observed enhancement of highly pluripotent stem cells following telomere mimic treatment. The most likely targets for telomere binding protein antagonism are TRF1 and TRF2, proteins that bind directly to telomeres involved in controlling lengthening, regeneration and maintenance of telomere structure and function. There are no published reports and only preliminary experiments to demonstrate relationships between drug concentrations and telomere binding protein TRF2 concentrations in cell nuclei. Project goal is to measure interactions between telomere binding protein antagonists and telomere binding proteins. There are no published reports and only preliminary experiments that demonstrate relationships between telomere mimic concentrations and telomere binding protein TRF2 concentrations in the nucleus, this research measured interactions between telomere binding protein antagonists and telomere binding proteins, finding that the TAG9_1 oligonucleotides had the highest intensity bands on a Western Blot, followed by TAG9_2 when treated with TRF2 primary antibody.
Resource Type
Date Available
Date Copyright
Date Issued
Degree Level
Degree Grantor
Advisor
Committee Member
Non-Academic Affiliation
Keyword
Rights Statement
Language
Replaces
Additional Information
  • description.provenance : Made available in DSpace on 2012-06-11T19:00:05Z (GMT). No. of bitstreams: 2 VanGardeRory seminar presentation 06-15-11.pdf: 897588 bytes, checksum: d3f92f6f2cf6b377aa4f5fd8fe4fee53 (MD5) VanGarde Rory Thesis June 10.pdf: 582013 bytes, checksum: 9a98a7af18c93c86cbbddda515e6bfa5 (MD5)
  • description.provenance : Submitted by Wanda Crannell (crannelw@hort.oregonstate.edu) on 2012-06-11T19:00:05Z No. of bitstreams: 2 VanGardeRory seminar presentation 06-15-11.pdf: 897588 bytes, checksum: d3f92f6f2cf6b377aa4f5fd8fe4fee53 (MD5) VanGarde Rory Thesis June 10.pdf: 582013 bytes, checksum: 9a98a7af18c93c86cbbddda515e6bfa5 (MD5)

Relationships

In Administrative Set:
Last modified: 07/27/2017 Default
Citations:

EndNote | Zotero | Mendeley

Items